INTRODUCTION
Pseudomonas aeruginosa is an opportunistic pathogen that causes infections in immunocompromised individuals, such as patients with burn wounds or leukaemia, and can cause chronic infections in cystic fibrosis patients [1] [2] [3] [4] . One virulence strategy used by the opportunistic pathogen P. aeruginosa is to target toxic proteins into eukaryotic cells by a type III secretion mechanism, a delivery mechanism utilized by several Gram-negative bacteria and plant pathogens [5] [6] [7] [8] [9] . Two P. aeruginosa toxins that are secreted and translocated into eukaryotic cells are exoenzyme S (ExoS) and exoenzyme T (ExoT) [10] . These proteins are highly homologous and both have been shown to possess ADPribosylation activities in itro [8, 11] . Previous studies show that ExoT, like ExoS, alters the cell morphology of Chinese hamster ovary cells [6, 12, 13] and inhibits uptake by corneal epithelial cells [14] , but the exact role of ExoT during infection is unknown.
ExoS is able to ADP-ribosylate Ras and several related proteins in itro [15, 16] , while no ADP-ribosylation target for ExoT has been identified. ExoS is a bifunctional toxin ; in addition to its Cterminal ADP-ribosylation activity in i o [6, [17] [18] [19] , ExoS has an N-terminal Rho GTPase-activating protein (GAP) activity in itro [20] . In addition, a eukaryotic factor activating ExoS, or FAS factor, is required to activate ExoS in cells [21] . FAS is a member of the 14-3-3 protein family [22] , and this interaction between 14-3-3 and ExoS is critical for Ras ADP-ribosylation by ExoS [21] [22] [23] . ExoT also possesses a C-terminal ADP-ribosyltransferase domain in itro [10, 24] and an N-terminal Rho-GAP domain, which shows efficient GAP activity towards Rho GTPases in itro [12, 25, 26] .
To investigate further the mechanism of ExoS and ExoT action\toxicity, we have focused on the identification of in i o targets for the ExoS and ExoT ADP-ribosylation activities. Ras and related proteins belong to a superfamily of small GTPbinding proteins, which can be divided into five subfamilies : Ras, Rho, ADP-ribosylation factors (ARFs), Rab and Ran. The Ras subfamily is involved in cell proliferation, differentiation, as well as progression through the G " phase and cell survival [27, 28] . The Rho family with its three major subfamilies, Rho, Rac and Cdc42, is involved in the control and reorganization of the cytoskeleton, as well as regulation of gene transcription [29, 30] . The ARF GTPase family is an important player in several vesicular trafficking pathways [31] . The Rab family, which contains at least 30 members, is involved in the secretory and endocytic pathways. Rab GTPases facilitate the formation of v-SNARE-t-SNARE complexes (where SNARE is soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor, v is vesicle and t is target), which are integral components of vesicle trafficking [31] . Finally, the Ran subfamily plays a role in nuclear trafficking [32] .
In this study we show that ExoS is a promiscuous ADPribosyltransferase. In itro, ExoS is able to modify all GTPases tested. However, in i o infection of eukaryotic cells with ExoS does not result in ADP-ribosylation of RhoA, RhoB, RhoD, Rab4, Rab27, TC21, ARF3 or Ran. In contrast, the related ExoT shows no detectable in i o ADP-ribosylating activity towards any of the GTPases tested. Further evidence for ExoS being the major ADP-ribosylation activity towards the small GTPases in i o comes from analysis of cells infected with different P. aeruginosa strains. We show that deletion of the gene encoding exoS results in an inability of P. aeruginosa to modify any small GTPases in i o. We further show that the bifunctional ExoS protein not only modifies, but also modulates, the activation state of several proteins, such as Ras, Ral, Rap1, Rap2, Rac1, RhoA and Cdc42 in i o. In conclusion, we suggest that the function of ExoS in i o is to perturb activation of not just one, but multiple small GTP-binding proteins and their effector signal-transduction pathways.
MATERIALS AND METHODS

Cell cultures and bacterial strains
HeLa cells were grown as described previously [12] . Bacterial strains used in this report, P. aeruginosa strains 388 (wild-type) [11] , 388∆exoS :: Tc [33] , 388exoT :: Tc [10] , Yersinia pseudotuberculosis expressing ExoS [YPIII( pIB251, pTS103)], ExoS(E381A) [YPIII(pIB251, pTS106)], ExoS(∆98-232) [YPIII(pIB251, pTS103 ; ∆98-232)], ExoT (YPIII 251, pCS100) and for mock infection, YPIII(pIB251), have been described previously [12, 19] . Bacterial cultivation and infection procedures were carried out as described previously [12] .
Plasmids and antibodies
pcDNA3-MT-Rab4, pSG5-HA-RalA, pCDNA3-MT-Rap1, pGEM-MT-Rab5a, pRK5-MT-R-Ras and pcDNA3-MTRhoA, B and D were kindly given by Dr M. Cormont, Dr H. Gille, Dr A. Hall and Dr H. Mellor. pMT-HA-Rap1, pMT-HARap2 and pMT-HA-PDZGEF were kind gift of Dr B. Burgering. Anti-Ras and Ras-related antibodies were purchased from Transduction Laboratories (Lexington, KY, U.S.A.). Polyclonal ExoS antibodies were produced by Agrisera (Umea/ , Sweden) [6] . Antibodies towards TC21, RhoA, Cdc42, R-Ras, K-Ras and NRas were purchased from Santa Cruz Biotechnology. Forskolin, 3-isobutyl-1-methylxanthine (IBMX), lysophosphatidic acid (LPA), ionomycin and bradykinin were purchased from Sigma. Epidermal growth factor was from UBI (Lake Placid, NY, U.S.A.) and platelet-derived growth factor (PDGF) was from R&D Systems. Glutathione-Sepharose 4B was obtained from Amersham Biosciences.
Transfection, cell lysis and immunoprecipitation
HeLa cells were transfected in 100 mm plates using the AMINE TM kit (Gibco BRL) according to the manufacturer's instructions. Cells were washed twice in ice-cold PBS and lysed on ice in lysis buffer [1 % Triton X-100, 100 mM NaCl, 50 mM Tris\HCl, pH 7.5, and 1 mM EDTA, supplemented with protease inhibitors (10 µg\ml aprotinin, pepstatin and leupeptin)]. Lysates were cleared by centrifugation at 15 000 g for 10 min at 4 mC. Equal amounts of cell lysates were incubated with 5 µg of anti-Myc antibodies cross-linked to Protein G beads as described [34] . After four washes in lysis buffer, samples were boiled in SDS sample buffer followed by immunoblotting. pMT-HA-Rap1, pMT-HA-Rap2 and pMT-HA-PDZGEF were transfected as above but harvested as described in [35] .
In vitro modification of Ras superfamily
GTPases were [$&S]methionine-labelled (Amersham Biosciences catalogue no. PB10282) by in itro transcription\translation in a coupled reticulocyte lysate system according to the manufacturer's instructions (TT2T7 coupled reticulocyte lysate system ; Promega). Each translation mix (2 µl) was then incubated with reaction buffer and 2 µl of secreted ExoS, as described previously [6, 19] . Samples were analysed by SDS\PAGE (12.5 % gels) followed by autoradiography.
Actin staining
The cells were grown on collagen I-coated 8-well culture slides (0.5i10& cells\well ; Becton-Dickinson). At time points after infection, 1 h and overnight, the cells were fixed with 2 % paraformaldehyde for 5 min, washed twice with PBS and permeabilized with 0.15 % saponin for 10 min. The actin microfilaments were stained with FITC-conjugated phalloidin for 30 min at 37 mC. Coverslips were mounted in a mounting medium containing CitiFluor (City University, London, U.K.) as an antifading agent. Disruption of the actin microfilaments was analysed using fluorescence microscopy.
In vivo Ral, Rap1/2, Rac, Rho, Cdc42 and Ras activation assays GTPase fusion proteins were purified and employed as described previously : GST-Raf1-Ras-BD [36] , GST-RalGDS-Rap1\2-BD [37, 38] , GST-PAK-Rac-BD and GST-WASP-Cdc42-BD [39] , GST-Rhotekin-Rho-BD [40] and GST-RalBP1-Ral-BD [41] (where GST is glutathione S-transferase, RalGDS is Ral GDP\ GTP dissociation stimulator, PAK is p21-activated kinase, WASP is Wiskott-Aldrich syndrome protein and BD is binding domain). Cells were stimulated and infected as indicated in the Figures. Equal volumes of lysates were incubated with GSTfusion protein beads at 4 mC for 1 h, washed and bound GTPase was separated on SDS\PAGE, followed by immunoblotting. Whole-cell lysates were also analysed for the presence of GTPase, as indicated in the Figures. Depending on cell conditions and different batches of GST-GTPase-BD, the GTPase-bound protein accounts for 1-5 % of total GTPase. Each series of infection and subsequent GST-fusion pull-down assay was carried out at least three times for each endogenous GTPase.
RESULTS
ExoS is a promiscuous ADP-ribosylation enzyme in vitro
It is well established that Ras is a target for ExoS ADPribosylation activity [15, 17, [42] [43] [44] [45] [46] [47] [48] . Since there is a high similarity among the family members of the small GTPases, we investigated whether small GTP-binding proteins other than Ras could also be modified by ExoS. To achieve this, we first tested ExoS for its in itro ability to ADP-ribosylate a number of small GTPases : Ha-Ras, RalA, RhoA, RhoB, RhoD, Cdc42, Rac1, Rab5, Rab4 and Rap1. GTPases were $&S-labelled in itro and tested for ADP-ribosylation modification activity using ExoS (Figure 1 ). We and others have earlier reported that the slower-migrating Ras protein is a consequence of ADP-ribosylation by ExoS [6, 15, 17, 19] . Interestingly, Ras, Rap1, Rap2 and Ral contain a conserved arginine residue at amino acid 41, which has been identified as the target for ADP-ribosylation in Ras [17, 44] . While many members of the Ras superfamily do not contain an arginine at amino acid 41, they do contain arginine residues in flanking sequence regions, which are potential sites for ADPribosylation. In our experiments all tested GTP-binding proteins show a slower mobility after incubation with ExoS ( Figure 1) . Thus ExoS is able to modify all GTPases tested in itro [15] .
ExoS ADP-ribosylates multiple GTPases in vivo
We have previously shown that ExoS ADP-ribosylates Ras, using the Y. pseudotuberculosis type III secretion system as a tool to deliver ExoS proteins into cells [19] . The advantage of using the Yersinia system is the opportunity to study the effects of ExoS and ExoT in the absence of other toxins. HeLa cells were infected with Y. pseudotuberculosis expressing either ExoS or ExoT as described previously [6, 12] . In addition, we also infected HeLa Modulation of the activity of small GTPases by exoenzyme S
Figure 1 ExoS ADP-ribosylation activity in vitro
Various small GTP-binding proteins, as indicated, were [ 35 S]methionine-labelled by in vitro transcription/translation and mixed with bacterially secreted ExoS, as described in the Materials and methods section, and thereafter separated by SDS/PAGE (12.5 % gels) and detected by autoradiography.
Figure 2 ADP-ribosylation activities of ExoS and ExoT in vivo
HeLa cells were infected for 80 min with Yersinia expressing different variants of ExoS and ExoT. Cells were lysed and samples were separated by SDS/PAGE (12.5 % gels). Western-blot analysis was performed on immunoblotted filters towards GTPases as indicated. Lanes 1, uninfected ; lanes 2, mock infection ; lanes 3, ExoS(E381A) ; lanes 4, ExoS ; lanes 5, ExoT. cells with bacteria expressing ExoS(E381A), a mutation (Glu3814Ala) that decreases ADP-ribosylation activity 2000-fold [6, 18] . After infection, HeLa cell lysates were analysed by immunoblotting against a variety of endogenous small GTPases ( Figure 2 ). We also examined HeLa cells transiently transfected with Myc-tagged RhoD, which were subsequently immunoblotted with anti-Myc antibodies (Figure 2 ). The effect of ExoS on the different Ras-related proteins was surprising ; we observed that H-Ras, N-Ras, K-Ras, R-Ras, Rap1, Rap2, Rab5, Rab8, Rab11, RalA, Cdc42 and Rac1 are ADP-ribosylated by wildtype ExoS in i o (Figure 2 , lanes 4). We were unable to observe modification of TC21, Ran, RhoA, RhoB, RhoD, ARF3, Rab4 or Rab27 (Figure 2 
ExoS is the major P. aeruginosa ADP-ribosylation toxin targeting host cell GTPases in vivo
The current literature regarding ExoS and ExoT function describes both as ADP-ribosylation enzymes [10, 24] . We wished to address the issue of whether ExoS or ExoT is responsible for GTPase modification by the P. aeruginosa host bacterium itself. This is an important question, since the relevance of ADPribosylation of ExoS and ExoT by P. aeruginosa during infection is unclear. In order to investigate this, we utilized the following
Figure 3 ExoS is the major Pseudomonas ADP-ribosylation activity towards small GTPases in vivo
HeLa cells were infected for 2.5 h with P. aeruginosa strains expressing both ExoS and ExoT (388), ExoS (388exoT :: Tc) or ExoT (388∆exoS :: Tc). Cells were lysed and samples were separated by SDS/PAGE (12.5 % gels). Western-blot analysis was performed on immunoblotted filters as indicated in the Figure. P. aeruginosa strains : (i) 388 wild-type, expressing both ExoS and ExoT [11] , (ii) 388∆ExoT, expressing ExoS but not ExoT [10] , and (iii) 388∆ExoS, which expresses ExoT but not ExoS [33] . This panel of P. aeruginosa strains was used to infect HeLa cells and to study the in i o effect of ExoS and ExoT on multiple members of the Ras superfamily. In order to assess GTPases modification in i o, HeLa cells were infected for 2.5 h. Lysates were separated on SDS\PAGE and immunoblotted with antiRas and Ras-related antibodies as before ( Figure 3) .
Our results were identical with those of our previous infections (Figure 2 ), where the type III secretion system of Yersinia delivered ExoS and ExoT. In the case of infection by P. aeruginosa 388 (wild type) and 388∆ExoT strains, both of which express and secrete ExoS, small GTPases were modified in a promiscuous manner. We observed that while TC21, ARF3, Ran, RhoA, RhoB, RhoD, Rab4 and Rab27 were not modified by ExoS in i o, all other Ras and Ras-related proteins tested were modified by the P. aeruginosa strains 388 and 388∆ExoT ( Figure 3 , lanes 2 and 3). This implies that ExoT is not required in i o for ADPribosylation of the small GTPases. If ExoT is not required for this modification in i o, one would then predict that a strain mutated for exoS, but still carrying a functional exoT gene, would not be capable of modifying Ras-family proteins in i o. This is in fact the case, since analysis of HeLa cells infected by the P. aeruginosa 388∆ExoS strain, which carries and expresses ExoT but not ExoS, is completely unable to modify any of the small GTPases analysed in i o ( Figure 3 , lanes 4). Since loss of ExoS expression completely abrogates the ability of P. aeruginosa to target and modify the small GTPases tested in i o we conclude that ExoS is the major ADP-ribosylating activity directed against host small GTPases encoded by P. aeruginosa.
ExoS ADP-ribosylation activity in vivo
We wished to address whether the different ExoS variants used above resulted in changes in the morphology of the infected cells. To achieve this, we used ExoS, ExoS(E381A) and ExoS(∆98-232), the last of which is a mutant where the GAP domain has been deleted [19] . To investigate further the important role for survival, morphology and actin reorganization of the GAP and the ADPribosylation domains of ExoS upon infection, we performed a second experiment in which HeLa cells were infected for 1 h with ExoS and derivatives of ExoS and subsequently washed free of
Figure 4 Disruption of actin microfilaments by ExoS
Hela cells were infected with bacteria expressing ExoS (A and E), ExoS(E381A) (B and F), ExoS(∆98-232) (C and G) or uninfected (D and H), followed by FITC-phalloidin staining of the actin microfilaments. Infection was allowed to continue for 1 h (A-C), and thereafter the cells were washed free of bacteria and incubated overnight with medium containing gentamicin (E-H). bacteria and incubated overnight with medium containing gentamicin. We observed that cells transiently infected with the ADPribosylation mutant ExoS(E381A) recovered their original cell structure and morphology overnight (Figure 4 , compare panel F with panels H and B), suggesting that infection with ExoS(E381A), which contains GAP activity and dramatically reduced ADP-ribosylation activity, results in a reversible phenotype. In contrast, cells infected with either wild-type ExoS or ExoS(∆98-232) for 1 h, washed and left overnight to recover, were profoundly different in their appearance (Figure 4 , compare panels E and G with panels F and H). These cells exhibited a sustained changed morphology, they were semi-detached from the Petri dish and were not healthy. Both the wild-type ExoS and ExoS(∆98-232) proteins harbour the ADP-ribosylation domain and the putative activity towards GTPase-defined target protein(s). Thus, via an as yet uncharacterized target, the ADPribosylation domain of ExoS appears to mediate non-reversible disruption of actin microfilaments. Thus these results provide strong evidence for a cellular target for the ADP-ribosylation activity of ExoS upon infection.
ExoS infection modifies Ras GTPase activation in vivo
The C-terminus of ExoS ADP-ribosylates Ras in i o and inhibits GTP loading and activation of Ras and its ability to interact with Raf upon stimulation with growth factors [19] . Previous work has also shown that the N-terminal GAP domain of ExoS, excluding the ADP-ribosylation domain, can inactivate Rho, Rac and Cdc42 in itro [20] . To extend and test directly whether ExoS modification modulates the activity of other small GTPases, pull-down assays were employed using specific downstream substrate proteins for the various GTPases under investigation. As we have detected ADP-ribosylation of several members of the Ras family members in i o (see above), we wished to examine any changes in in i o activity status of a selection of these small GTPases. Those chosen for further in i o studies were Ras, Ral, RhoA, Cdc42, Rac1, Rap1 and Rap2.
The small GTPase Ras plays a critical role in activation of several downstream cascades, which are involved in both regulated and de-regulated cell proliferation, as well as the control of differentiation and progression through the G " phase. In addition, Ras has been implicated in cell survival [27, 28] . HeLa cells were infected with Y. pseudotuberculosis expressing wild-type ExoS, ExoS(E381A) or ExoS(∆98-232) [19] . We have shown that wild-type and mutant proteins are equally and efficiently expressed and translocated into HeLa cells [6, 19, 49, 50] . Ras activation was measured in i o by GST-Raf-Ras-BD pull-down assays. Treatment of uninfected cells with fetal calf serum (FCS) increased the affinity precipitation of Ras by GST-Raf-Ras-BD, reflecting Ras activation ( Figure 5A, lane 2) . No co-precipitation of Ras with GST-Raf-Ras-BD upon FCS stimulation was observed after infection with bacteria expressing wild-type ExoS or ExoS(∆98-232) ( Figure 5A, lanes 5 and 6) . Conversely, coprecipitation of Ras protein with GST-Raf-Ras-BD was detected upon stimulation with FCS after infection with ExoS(E381A) ( Figure 5A, lane 4) . Thus ExoS ADP-ribosylates Ras in i o ( Figure 5B , compare lanes 5 and 6 with 3 and 4) and inhibits GTP loading and activation of Ras and its ability to interact with Raf upon stimulation with growth factors, as we have reported previously upon stimulation with epidermal growth factor [19] .
Ral GTPase is down-regulated by the ADP-ribosylation domain of ExoS
The Ras-like family of small GTPases includes, among others, Ras, Rap1, R-Ras and Ral. These proteins are classified in this group based upon similarities in the effector domain [27, 28] . Similar to Ras, Ral proteins are active when GTP-bound. The exchange is catalysed in i o by the Ral guanine nucleotide exchange factors (Ral-GEFs) [51] . Observations that mitogendependent activation of Ral proteins requires Ras activation have led to the suggestion that Ral-GEFs are Ras effector proteins, and that Ral is required for Ras-induced oncogenic growth, morphological transformation and induction of DNA synthesis [27, [52] [53] [54] . Recently it has been suggested that the Ras\Ral pathway might affect the activity of the Forkhead box (FOXO4) transcription factor [55] . This suggests that Ral might be an important mediator of Ras-induced proliferation and survival signals, although the direct signal transduction pathways downstream of Ral and its effector Ral-binding protein 1, which associates with Ral in a GTP-dependent manner, have not been resolved [55] [56] [57] . We have already established that infection with ExoS down-regulates Ras [19] , and since Ral is suggested to be a downstream target of Ras upon growth factor stimulation we wished to investigate the activity of Ral using a Ras-independent pathway. Calcium can activate Ral independently of Ras [41, 58] . To monitor the activation of Ral, we employed pull-downs with the Ral-BD of RalBP1 [41] . Treatment of uninfected cells with ionomycin increased the affinity precipitation of Ral by GSTRalBP1-Ral-BD ( Figure 6A, lanes 1 and 3) . No co-precipitation of Ras with GST-Raf-Ras-BD upon ionomycin treatment was observed ( Figure 6C, lanes 1 and 3) . On the other hand, both Ras and Ral could be affinity precipitated upon stimulation with FCS using GST-Raf-Ras-BD and GST-RalBP1-Ral-BD, respectively (compare Figures 6A and 6C, lanes 1, 2 and 3) . The activation of Ral reached maximal levels after 2 min stimulation with ionomycin (results not shown). After infection with ExoS or ExoS(∆98-232) for 80 min, followed by stimulation with ionomycin, we could observe a clear ADP-ribosylation of Ral and Ras in i o ( Figures 6B and 6D, lanes 6 and 7) . However, no coprecipitation of Ral proteins was detected employing the GSTRalBP1-Ral-BD pull-down technique ( Figure 6A , compare lane 3 with lanes 6 and 7). Infection with ExoS(E381A), prior to stimulation with ionomycin, does not abrogate Ral protein activation and resulting precipitation with GST-RalBP1-BD, suggesting that ExoS does not increase the intrinsic GAP activity of Ral-GTP. Thus ExoS appears to inhibit Ral-mediated signal transduction via ADP-ribosylation in i o.
Modulation of Rap1 and Rap2 by ExoS in vivo
The small GTPase Rap1 can inhibit Ras transformation by binding to downstream effectors of Ras signalling, but has lately also been suggested to be involved in a variety of biological processes, such as control of cell morphology, adherens junction positioning and cell adhesion [27, 59, 60] . Rap2 is also a member of the Ras-like family of GTPases and exhibits 60 % identity with Rap1, but the function and regulation of Rap2 are unknown [27, 28] . We analysed Rap1 and Rap2 activity in i o in response to ExoS infection. To study Rap activities in i o, the activation has to be carefully considered to ensure that analyses are not influenced by activation of Ras. Rap1 activation can be observed by an increase of intracellular cAMP, which activates the Rap1 and Rap2 specific guanine exchange factor, named Epac [27, 38, 61] . In Figure 7 we show that a combination of forskolin and IBMX activates both Rap1 and Rap2 readily without a notable activation of Ras, although upon stimulation with FCS all three GTPases, Ras, Rap1 and Rap2, were activated ( Figures  7A, 7C and 7E, compare lanes 1, 2 and 3) . Whole cell lysate from cells that have been infected with ExoS wild-type and ExoS(∆98-232), both of which contain the ADP-ribosyltransferase domain, were able to modify both Rap1 and Rap2, whereas ExoS(E381A) showed no ADP-ribosylation activity towards Rap1 and Rap2 ( Figures 7B, 7D and 7F, compare lanes 1, 2 and 5 with lanes 6 and 7). We monitored activity of both endogenous Rap1 and Rap2 using pull-downs with the Rap downstream target, GSTRalGDS-Rap1-Rap-BD, after infection with ExoS and ExoS(∆98-232) ( Figures 7A and 7C, lanes 6 and 7) . Cells infected with the ribosylation-negative ExoS(E381A) mutant showed reduced Rap1 activation. A significant reduction was not observed with Rap2, indicating that the GAP domain of ExoS is a functional Rap1 GAP, but does not appear to function as a GAP for Rap2 ( Figures 7A and 7C, compare lanes 4 and 5) . In order to establish further that ExoS(E381A) does not target Rap2 with its GAP domain, we extended our analysis to cells transiently transfected with haemagglutinin-tagged Rap2 in the presence or absence of haemagglutinin-tagged-PDZ-GEF, the exchange factor for Rap1. As we observed previously, infection with ExoS modifies the transiently transfected haemagglutinintagged Rap2, and we observed a decreased binding of haemagglutinin-tagged Rap2 with GST-RalGDS-Rap-BD, but not after infection with ExoS(E381A), similar to that observed above with the endogenous proteins (results not shown). Thus, both Rap1 and Rap2 are modified by ExoS. ADP-ribosylation of Rap1 and Rap2 results in decreased activity, as measured by interaction with the downstream target, GST-RalGDS-Rap-BD. In addition, ExoS also appears to function as a GAP for Rap1 in i o, which was not observed for Rap2. Thus ExoS shows differential GAP activity towards Rap1 and Rap2. 
Figure 7 Precipitation of active Rap1/2 with GST-Rap-BD of RalGDS
GAP-deficient ExoS protein activates Rac
The small GTPases of the Rho subfamily are key signal transducers, associated with cytoskeletal reorganization. The Rho subfamily proteins are suggested to be important in several cellular processes, such as cell shape determination, migration, transcriptional regulation and vesicle trafficking [29, 30] . Rho proteins are targets for several toxins that covalently modify Rho, such as C3, which inactivates Rho by ADP-ribosylation of Arg-41 [62, 63] . Toxins A and B from Clostridium difficile inactivate Rho by monoglycosylation at Thr-37, but also Rac and Cdc42 [64, 65] . Cytotoxic necrotizing factor, conversely, activates Rho, Rac and Cdc42 by deamidation of Gln-63 [66, 67] . Several other toxins have been suggested to regulate the active versus the inactive state of Rho, including ExoS, ExoT, SptP and YopE, which act as GAP proteins for several members of the Rho family in itro [12, 20, [68] [69] [70] [71] [72] . However, the in i o activity of these GAPs has never been addressed. Pull-down assays for determining levels of active GTP-bound Rho, Rac and Cdc42 in cells using recombinant domains of target proteins (PAK for Rac, WASP for Cdc42 and Rhotekin for Rho) have become a rapid and central tool to establish the GTP\GDP ratio, i.e. the active\inactive state, of Rho, Rac and\or Cdc42 [39, 40, 73] .
We have employed PDGF stimulation to activate Rac in HeLa cells (Figure 8, compare lanes 1 and 2) . The same variants of ExoS proteins were employed as above. Cells infected with the ADP-ribosylation-negative ExoS(E381A) mutant, followed by stimulation with PDGF, showed a reduced Rac activation as measured by GST-PAK-Rac-BD pull-downs (Figure 8 , compare lanes 4 with 1). This indicates that the ExoS GAP domain has the capacity to function as a Rac-GAP in i o, as predicted from the in itro analysis. Unexpectedly, we observed that cells infected with the wild-type ExoS followed by stimulation with PDGF showed a similar or slightly increased ability to interact with GST-PAK-Rac-BD compared with uninfected cells, and the Rac proteins that were precipitated were modified (Figure 8, lanes 5) . Thus, full-length ExoS appears, if anything, to activate Rac in i o. Furthermore, and even more surprisingly, in cells infected with ExoS(∆98-232), which contains the ADP-ribosylation domain of ExoS but lacks the GAP domain, we observed a dramatic increase of Rac in a GTP-bound state upon stimulation with PDGF compared with the wild-type ExoS (Figure 8 , compare lanes 6 with 7). Thus loss of the N-terminal GAP domain of ExoS results in an ExoS, which activates the small GTP-binding protein Rac. From our analysis of Rac activity in i o it is clear that ExoS is able to ADP-ribosylate Rac ; however, this modification does not appear to modify significantly Rac activity in i o. Furthermore, it is clear that alone the ADPribosylation domain of ExoS acts as a robust Rac activator.
ExoS is a functional Rho-GAP in vivo
RhoA proteins can be activated readily by stimulation with LPA [40, 74] . HeLa cells infected with the ADP-ribosylation-negative ExoS(E381A) mutant, followed by stimulation with LPA, show a reduced Rho activation, as measured by GST-Rhotekin-Rho-BD pull-downs (Figure 9, compare lanes 4 with 1) . These results indicate that the GAP domain of ExoS is a functional Rho-GAP in i o. Similar to ExoS(E381A), infection with wild-type ExoS followed by stimulation with LPA also inhibits endogenous RhoA activation (Figure 9 , lanes 5). Infection with ExoS(∆98-232), which contains only the ADP-ribosylation domain, also inhibits Rho activation ( Figure 9, lanes 6 ). This may be due to the higher ADP-ribosylation activity of this deletion mutant as compared with ExoS ( Figure 9, lanes 5 and 6) , since an ADPribosylated RhoA protein can be observed in the whole cell lysate after infection for 80 min. Similar to our analysis of Rac, above, this suggests that great care should be taken when interpreting results achieved with deletion variants of ExoS. In conclusion, ExoS appears to act as a GAP for Rho in i o, while the contribution of ADP-ribosylation to this modulation of Rho activity in i o appears to be slight, if significant at all.
ExoS acts as a GAP for Cdc42 in vivo
Cdc42 can be activated by stimulation with bradykinin and, similar to microinjection of activated Cdc42, filapodial protrusions can be observed [73, 75] . Cells infected with the ExoS(E381A) mutant, followed by stimulation with bradykinin, show a clear reduction of Cdc42 activation, as measured by GST-WASP-Cdc42-BD precipitation (Figure 10 , compare lanes 4 with 1). A significant proportion of the Cdc42 protein pool appears to be down-regulated by both ExoS(E381A) and wildtype ExoS, thus indicating that the GAP domain of ExoS is a functional Cdc42 GAP. These observations are in agreement with the in itro observations, which have suggested that ExoS contains a GAP activity against Cdc42 [20] . Similar to our results with RhoA above, the ADP-ribosylation domain of ExoS, lacking the GAP domain, also impairs the precipitation of Cdc42 with the GST-WASP-Cdc42-BD mutant.
DISCUSSION
In this report we have focused on two analyses. Firstly, we wanted to ask which of the small GTPases are modified in i o by ADP-ribosylation, specifically by the toxins ExoS and ExoT of P. aeruginosa. Secondly, after identifying multiple endogenous small GTP-binding proteins as in i o ribosylation targets for ExoS, we asked if these modifications resulted in a modulation of small GTPase activity in i o. In our studies we have employed a clinical isolate of P. aeruginosa as well as genetically engineered Y. pseudotuberculosis strains to deliver ExoS proteins into eukaryotic cell cytosol [6, 10] . The latter type III secretion system allows direct measurements of the consequence of individual type III translocated cytotoxins on cell physiology ( [6] and references therein). We have investigated two bifunctional toxins, ExoS and ExoT. In itro studies have shown that both toxins contain GAP activity together with a ADP-ribosyltransferase domain. Our initial analysis employed recombinant ExoS protein in itro, which should provide an initial indication of ADPribosylation observed as an increase in protein mass due to the ADP-ribosylation of small GTPases. Secondly, we have examined ADP-ribosylation in i o by the shift in protein mass 
of endogenous small GTP-binding proteins following infection by bacteria expressing ExoS and ExoT. These results, summarized in Table 1 , show that ExoS displays a highly promiscuous ADP-ribosylation activity towards small GTPases, both in itro and also in i o. All tested GTP-binding proteins in itro show a slower mobility after incubation with ExoS, thus ExoS is able to modify all GTPases tested in itro [15, 76] . Upon infection with ExoS in i o the effect of ExoS on the different Ras-related proteins was more restricted ; we observed that H-Ras, N-Ras, K-Ras, R-Ras, Rap1, Rap2, Rab5, Rab8, Rab11, RalA, Cdc42 and Rac1 are all ADP-ribosylated by ExoS in i o. However, we were unable to observe modification of TC21, Ran, RhoA, RhoB, ARF3, Rab4 or Rab27. In contrast, ExoT shows no detectable ADP-ribosylating activity towards any of the GTPases tested in i o, regardless of whether ExoT protein is secreted and translocated by the type III system of P. aeruginosa or by Y. pseudotuberculosis. Since a strain of P. aeruginosa deleted for ExoS has no detectable in i o small G-protein ADP-ribosylation activity and ExoT has no identifiable ADP-ribosylation activity against the GTPases tested here, we suggest that ExoS is the major ADP-ribosyltransferase protein in P. aeruginosa towards the small GTPases. One is then left to consider the target of the putative in i o ADP-ribosylation activity of ExoT on cellular infection by P. aeruginosa. Interestingly, in our previous studies [12] , we observed that ExoT(R149K), which is deficient in GAP activity, is still able to cause a morphological change in infected HeLa cells. This is of importance, since it suggests that the ADP-ribosylating activity of ExoT targets another, as yet unidentified, host protein that is distinct from the Ras family members examined here. It should be emphasized that our observations of ADP-ribosylation activity by ExoS on in i o substrates are identical using two different systems, with both Pseudomonas and Yersinia strains. Our observations are strengthened since they are in agreement with Olson and co-workers [77] , who have compared twodimensional electrophoresis of substrate modifications by ExoS in itro with that following bacterial translocation in cells. It has been reported by Vidal and co-workers [16] that ExoS ADPribosylation of Rab4 in permeabilized reticulocytes affects Rab4's function in membrane recycling, but the mechanism behind this inhibition is unclear [16] .
In i o studies with ExoS have shown that the expression of ExoS affects cell viability [6] , and to date this effect on viability has been considered most probably as a result of ADPribosylation of Ras [19] , which has a central role in cell signalling. We wished to examine changes in in i o activity status of a selection of the small GTPases, which we had identified as the ExoS ADP-ribosylation substrates in i o. To extend and directly test whether ExoS modification modulates the activity of these small GTPases, pull-down assays using specific downstream substrate proteins for the various GTPases under investigation were employed (summarized in Table 2 ). As we have reported previously [19] , ExoS ADP-ribosylates Ras in i o and inhibits GTP loading and activation of Ras and its ability to interact with Raf upon stimulation with growth factors. Bacterially secreted ExoS in i o shows no GAP activity towards endogenous Ras, in agreement with in itro reports [20] .
We also studied the modulation of Ral activity by ExoS. It has recently been proposed that Ras\Ral pathway might affect the activity of further downstream transcription factors, such as Forkhead box (FOXO4) [55] . This suggests that Ral might be an important mediator in proliferation and survival, although the direct signal transduction pathways downstream of Ral have not been resolved [55] [56] [57] . We observed a clear ADP-ribosylation activity towards Ral in i o with both Pseudomonas and Yersinia strains (which exclusively express ExoS). Furthermore, Ral activity was inhibited after ExoS infection. Since the ADPribosylation-deficient ExoS mutant did not appear to affect Ral activity, we presume that ExoS does not act as an efficient GAP for Ral in i o. Thus, ExoS appears to inhibit Ral-mediated signal transduction via ADP-ribosylation in i o. While the molecular mechanism behind this inhibition is unclear, it is possible that the ADP-ribosyl modification of Ral hinders the interaction between Ral and RalBP1, although it is also plausible that the modification hampers the postulated exchange activity for Ral [17] . Further in i o studies of this matter are required.
Rap1 and Rap2 are also members of the Ras-like family of GTPases and exhibit high homology to Ras in the effector domain [27, 28] . We explored the modification of Rap1 and Rap2 activity in i o in response to ExoS infection. The modification of Rap proteins by ExoS is a controversial area, since it has previously been reported that Rap1 is not modified in i o by ExoS [43] . However, we see a clear modification of Rap proteins by ExoS under conditions sufficient for Ras modification, in agreement with recent report of others (see above and [48, 77] ). Infection with full-length ExoS results in the ADP-ribosylation of Rap1 and Rap2 and the inhibition of Rap1 and Rap2 activation as measured by pull-down assay. Furthermore, the GAP domain of ExoS shows significant GAP activity towards Rap1 in i o. In our hands, however, Rap2 does not appear to be a significant target for ExoS GAP activity.
Several toxins have been shown to regulate the nucleotide state of Rho subfamily members and they act as GAP proteins for several members of the Rho family in itro [12, 20, [68] [69] [70] [71] [72] . However, the in i o GAP activity of toxins, such as ExoS, ExoT, SptP and YopE, has never been reported. Incorporation of GAP activities into this family of bacterial toxins offers a great advantage in the anti-phagocytic strategy during infection, and is further illustrated by the fact that all of these effectors proteins have been found to prevent bacterial internalization [6, 14, 69, 78] . We have investigated the in i o modulation of RhoA, Rac and Cdc42 after infection of ExoS. Cells infected with ADPribosylation-negative ExoS mutant show reduced Rac activation, as measured by pull-down assay. This indicates that the ExoS GAP domain functions as a Rac-GAP in i o, as predicted from earlier in itro results [20] . However, we observed that cells infected with wild-type ExoS showed a similar or slightly increased ability to interact with GST-PAK-Rac-BD, which was unexpected. Also surprising was the fact that the effector domain of ADP-ribosylated Rac was still able to interact with GST-PAK-Rac-BD. Furthermore, cells infected with a GAP-deficient ExoS, which contains a complete ADP-ribosylation domain of ExoS, showed a dramatic increase of Rac in a GTP-bound state, resulting in a robust activation of the small GTPase Rac. From our analysis of Rac activity in i o it is clear that ExoS is able to ADP-ribosylate Rac ; however, ADP-ribosylation in the context of the full-length ExoS molecule does not appear to modulate Rac activity significantly in i o, either negatively or positively. Loss of ExoS ADP-ribosylation activity (through mutation of the ADP-ribosylation domain) unveils a Rac GAP activity and subsequent Rac inactivation. Conversely, loss of GAP activity (through deletion of the GAP domain) in ExoS reveals a capacity of the ExoS ADP-ribosylation domain to activate potently Rac in i o. This experiment in particular highlights a drawback with using deletion variants of ExoS. The above results from two ExoS proteins, which are variants of the bifunctional enzyme ExoS, should be compared with the wild-type ExoS protein, which does not significantly modulate Rac activity in i o, though it is clearly able to ADP-ribosylate Rac. Possible explanations for these results are that the ADP-ribosylation of Rac by ExoS hampers the intrinsic Rac GTP-to-GDP hydrolysis. Another possibility is that the ADP-ribosyl modification may change the protein conformation of Rac in such a way that it neutralizes the GAP domain of ExoS. Alternatively, auto-ADPribosylation of ExoS mediates a GAP domain that is a poor activator of the intrinsic hydrolysis of Rac, which has been suggested in itro [79] . Finally, it is also possible that ribosylation of Rac by ExoS increases its activity for PAK independent of nucleotide loading. These results indicate that the mechanism of ExoS action is complex, and is likely influenced by its bifunctional mechanism of action. This experiment shows that deletion variants of proteins may not precisely reflect the in i o situation when bacteria translocate toxins to the eukaryotic cell. In agreement with earlier in itro reports, we observe that ExoS is also a functional Rho-GAP in i o. It should be noted that Rho activity is still observed after infection with ExoS, thus indicating that the GAP domain of ExoS does not down-regulate the entire pool of endogenous Rho proteins. Thus, ExoS appears to act as a GAP for Rho in i o, while the ADP-ribosylation is also able to contribute to the modulation of Rho activity in i o, although the relevance of this activity physiologically is unclear, since at later times of infection cells are no longer viable. Finally, cells infected with wild-type ExoS show a clear reduction of Cdc42 activation. A significant proportion of the Cdc42 protein pool appears to be down-regulated, indicating that the GAP domain of ExoS is a functional and fairly efficient Cdc42 GAP. These observations are in agreement with in itro observations, which have suggested that ExoS contains a GAP activity against Cdc42 [20] . However, Cdc42 is also inactivated by infection with a GAP-defective ExoS.
We have investigated seven selected small GTPases for in i o activities and their ability to interact with downstream targets, which affect downstream signalling pathways important for DNA synthesis, morphology, adhesion and microbial invasion, and survival (Table 2 ). From our analyses we observe that Ras, Ral and both Rap1 and Rap2 lose their ability to interact with downstream signalling proteins due to ADP-ribosylation activities after infection by wild-type ExoS. Cdc42 is modified by ExoS early after infection and ADP-ribosylation activities by ExoS clearly impair Cdc42's ability to interact with downstream targets. On the other hand, only Rap1, RhoA and Cdc42 were observed to be down-regulated by wild-type ExoS, through the GAP domain. Finally, we observed that the outcome after infection by wild-type ExoS on Rac1 is similar to stimulated uninfected cells, although Rac1 is ADP-ribosylated and has the ability to interact with the GST-PAK-Rac-BD. Further studies will define the importance of each individual modulation of different GTPases by ExoS and whether P. aeruginosa targets virulence proteins into the eukaryotic cytosol via a type III secretion-dependent mechanism as part of an anti-phagocytic strategy.
